drugset
drugset / Trial / NCT05524857

Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)

NCT05524857 ↗

Phase 1 Terminated 2 enrolled Joseph Jurcic Bristol-Myers Squibb · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this research is to study the safety and tolerability and to establish the maximum tolerated dose (MTD) of the combination of two drugs, fedratinib and decitabine, for the treatment of advanced-phase MPNs.

Timeline

Start
2022-01-28
Primary completion
2024-04-09
Completion
2024-04-09

Outcome

Outcome not reported

Stopped: “Closed by Sponsor”

Drugs

EvaluationDrugModalityDoseRoute
Subject Decitabine Small molecule 20 mg/m2 Intravenous
Subject Fedratinib Small molecule 300 mg Oral
Subject Fedratinib Small molecule 400 mg Oral

Indications

myeloproliferative neoplasm